RCEL · AVITA Medical, Inc.
$15.65
-1.06 (-6.34%)
At close · Oct 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”View the 10-Q filed Aug 6, 2026
Market Cap
$484.01M
Shares
30.93M
Volume · Oct 30
597.05K
Avg daily vol (3M)
484.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.65
Open$16.54
Day$15.24–16.60
52W close$3.27–16.71
Avg vol 30d391K
Short int2.8M · 9.2% float · 7.6d
Short vol52%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 1 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$75.63M
Trailing 12 months
Net income (TTM)
−$43.08M
Trailing 12 months
Revenue growth YoY
+17.8%
Year over year
Operating margin
-46.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$24.80M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.6%
Year over year · more shares
Price change (1Y)
+326.4%
Trailing year
Short interest
9.2%
Latest settlement · 7.6 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. AVITA Medical reported Q2 2026 record revenue of $21.7 million, up 18% year-over-year, raised full-year 2026 revenue guidance to $86-$89 million, and introduced new guidance to reach cash flow breakeven in Q4 2026.
Bullish
- + Q2 revenue grew 18% year-over-year and 13% sequentially to a record $21.7 million
- + Introduced new guidance to reach cash flow breakeven and begin generating cash in Q4 2026
- + Gross margin expanded to 81.9%, up 70 basis points year-over-year
- + Operating expenses declined 6% year-over-year to $24.6 million while revenue grew
- + Net cash use improved to approximately $3.2 million from $9.9 million in Q1 2026
- + Net loss improved to $7.7 million from $9.9 million in the prior-year period
Bearish
- − Cohealyx and PermeaDerm carry lower ASPs (50% and 60% respectively), pressuring overall gross margin percentage as they grow
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.4 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+139%
above
Price vs 50-day avg
+28%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+23%
trailing
6-month return
+258%
trailing
YTD return
+354%
this year
Relative strength
+256%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
16 of 74 funds reported for Sep 30 · net +27.1K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.17% of float · ▼ -1.8% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
74 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
82%
contracting
EPS growth
+27%
Y/Y
Free cash flow
$-32.2M
Balance sheet
$32.7M
net debt
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2026
Revenue guidance
· full year 2026
Raised
$86M – $89M
May 14, 2026
$80M – $85M
changed to
Aug 6, 2026
$86M – $89M
prior FY $71.61M
midpoint +22.2% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Nov 6, 2025
Full year revenue
· full year 2025
$70M – $74M
Guided vs delivered
· last 4 settled
Full year revenue
full year 2025
guided $70M – $74M
$71.61M
In line
Revenue
full-year 2024
guided $78.5M – $84.5M
$64.25M
Miss −21.2%
2023 annual revenue
full year 2023
guided $49M – $51M
$50.14M
In line
Total revenue
Second Quarter of Fiscal Year 2022
guided $7M
$8.34M
Beat +19.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+139%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
16 of 74 funds reported for Sep 30 · net +27.1K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.17% of float · ▼ -1.8% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
74 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $16 · 92%
Range high $17
vs 200-day avg +139%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $11.1M | Q2 2026 | — |
| Cohealyx revenue | $1.7M | Q2 2026 | — |
| Gross profit margin | 81.9% | Q2 2026 | +0.9% |
|
|
|||
| International revenue | $0.9M | Q2 2026 | — |
| Net cash use | $3.2M | Q2 2026 | — |
|
|
|||
| PermeaDerm revenue | $0.6M | Q2 2026 | — |
| RECELL revenue | $18.5M | Q2 2026 | — |
| RECELL-only gross margin | 86% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCEL
this stock
AVITA Medical, Inc.
|
$484.01M | +353.6% | +11.5% | — | 9.2% |
|
ABT
Abbott Laboratories
|
$184.98B | -15.2% | +5.7% | 34.4 | 1.0% |
|
MDT
Medtronic plc
|
$123.49B | +0.5% | +8.4% | 23.8 | 10.9% |
|
SYK
Stryker Corp
|
$111.11B | -17.0% | +11.2% | 31.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$60.84B | -56.0% | +12.5% | 17.0 | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCEL | +0.9% | +23.0% | +258.1% | +33.4% | +353.6% |
| SPY | -0.6% | -1.8% | +2.2% | -0.9% | +10.8% |
| vs SPY | +1.5% | +24.8% | +255.9% | +34.3% | +342.8% |